A spin-off company from the Department of Biotechnology at Lund University, Sweden, has announced it will start investigating if its technology platform can be used to diagnose and prevent many leading chronic diseases.
By using this technology platform, chronic diseases such as Type 2 diabetes, cardiovascular disease, arthritis, and some forms of cancer, as well as Alzheimer’s and dementia can be prevented.
Kristofer Cook, CEO of the spin-off company Carbiotix, said: “We have always had the ambition of leveraging our technology platform to develop, test, and increase the effectiveness of gut microbiome therapeutics.
“This new investigation into diagnosing, preventing and potentially even treating chronic conditions is a natural extension of this ambition and is based on very promising customer data we have generated after the recent launch of our personalised prebiotic fibre.”
Early detection is important
CTO of Carbiotix Peter Falck said that early detection is the most important factor.
He explained: “We have seen indications that an optimised and stable gut flora is highly sensitive to inflammation, one response the body has in the early stages of chronic disease development.
“This information could be used to alarm someone, like an early warning system, that they should visit a medical professional if the inflammation is sudden, sustained and unexplained.”
He added: “It may also be possible to link the activity of specific gut bacteria to the onset of a chronic condition; thus, we could potentially be able to diagnosis a chronic disease in real time, as our customers already have the routine of sending us monthly gut microbiome samples.”
What is Carbiotix’s approach?
Carbiotix’s approach focuses mainly on addressing the potential causes of chronic disease development rather than treating the symptoms, leveraging host probiotic bacteria and ‘food as medicine’ to restore and optimise the gut microbiome.
“We also think that an optimised and stable gut flora will generally result in less inflammation in the body (a suspected and potential trigger to the development of many chronic conditions) and an improved resistance against bacterial infections, potentially even rebounding to an optimal state much quicker after the use of antibiotics,” Falck added.
“The key to this approach is to first optimise and stabilise a person’s gut health through personalised soluble fibre consumption and monthly gut microbiome testing. At the end of the day, you can’t manage what you don’t measure.”
The benefits of the technology
Cook concluded: “Although we launched our technology platform less than six months ago, the results we are seeing in this timeframe are astonishing. Nearly all of our customers, including people with stated gastrointestinal problems, experience gut health improvements after 2-4 months, with some even reaching an optimised and stable gut flora in this timeframe.
“Since the rate of chronic disease development continues to grow around the world, it is now more important than ever to explore new and unconventional approaches, especially those that leverage the body’s own natural ability to repair itself.”
Press Release: My News Desk
